An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pracinostat in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Pracinostat (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Helsinn Healthcare SA
- 03 Aug 2018 Planned End Date changed from 30 Aug 2018 to 30 nov 2018.
- 03 Aug 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Oct 2018.
- 16 Apr 2018 New trial record